Dopavision https://dopavision.com/ Thu, 09 Jan 2025 16:57:58 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://dopavision.com/wp-content/uploads/2021/06/favicon-150x150.png Dopavision https://dopavision.com/ 32 32 Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference https://dopavision.com/2024/09/30/dopavision-presented-key-data-from-its-myopiax-1-clinical-trial-at-the-19th-international-myopia-conference/ Mon, 30 Sep 2024 13:01:27 +0000 https://dopavision.com/?p=11256 — First Data Presentation: Friday’s presentation marked the first public disclosure of the 6-month data from the MyopiaX-1 clinical trial in children with myopia (NCT04967287). — MyopiaX Clinical Outcomes: MyopiaX demonstrated positive proof of concept at six months, showing promise for future clinical studies. — Final Trial Visits:The 12-month MyopiaX-1 clinical trial is ongoing at sites in Europe and is […]

The post Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference appeared first on Dopavision.

]]> Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia https://dopavision.com/2024/05/28/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/ Tue, 28 May 2024 11:54:47 +0000 https://dopavision.com/?p=11186 — Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX’s excellent safety and tolerability profile with no untoward safety events. — Novel Approach: Dopavision’s approach to delivering targeted photobiomodulation to the eye shows signals of clinical effect on the rate of myopia progression. — New Alternative: The intervention delivered in an easy to use […]

The post Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia appeared first on Dopavision.

]]> Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial https://dopavision.com/2023/09/26/dopavision-reports-successful-completion-of-enrollment-for-myopiax-1-trial/ Tue, 26 Sep 2023 08:00:56 +0000 https://dopavision.com/?p=11113 – MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful […]

The post Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial appeared first on Dopavision.

]]> Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active https://dopavision.com/2023/06/28/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/ Wed, 28 Jun 2023 08:02:44 +0000 https://dopavision.com/?p=11027 – First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally– Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its MyopiaX-1 […]

The post Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active appeared first on Dopavision.

]]> Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer https://dopavision.com/2023/03/21/dopavision-appoints-prof-dr-jens-ellrich-as-chief-scientific-officer/ Tue, 21 Mar 2023 09:00:55 +0000 https://dopavision.com/?p=10973 – Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in digital […]

The post Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer appeared first on Dopavision.

]]> Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board https://dopavision.com/2022/11/16/dopavision-appoints-dr-dirk-sauer-as-chair-of-the-companys-advisory-board/ Wed, 16 Nov 2022 09:00:22 +0000 https://dopavision.com/?p=10759 – Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]

The post Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board appeared first on Dopavision.

]]> Printable Resources https://dopavision.com/2022/07/05/printable-resources/ Tue, 05 Jul 2022 13:08:33 +0000 https://dopavision.com/?p=10453 PRINTABLE RESOURCES Return to Portal Home Downloadable Resource Welcome letter Storyboard EN DOCPPT DE DOCPPT ES DOCPDF PT DOCPDF NL DOCPDF Daily schedule Activity cards Weekly schedule (1) Weekly schedule (2) Monthly schedule PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF Goal chart (1) Goal chart (2) PDFPDF PDFPDF PDFPDF PDFPDF PDFPDF At-home reward system Clinic reward system […]

The post Printable Resources appeared first on Dopavision.

]]> Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer https://dopavision.com/2022/05/25/dopavision-appoints-mark-s-wuttke-ph-d-as-chief-executive-officer/ Wed, 25 May 2022 09:15:01 +0000 https://dopavision.com/?p=10428 – Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]

The post Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer appeared first on Dopavision.

]]> FAQs https://dopavision.com/2022/04/28/faqs/ Thu, 28 Apr 2022 11:15:48 +0000 https://dopavision.com/?p=10320 FREQUENTLY ASKED QUESTIONS Technical FAQs Trial FAQs Return to Portal Home Technical FAQs Download all FAQs as a PDF This section provides guidance on how to respond to some common technical concerns with which caregivers may reach out to you. If you do not feel confident helping a caregiver with a technical question, please assure […]

The post FAQs appeared first on Dopavision.

]]> Report a Technical Issue https://dopavision.com/2022/04/21/report-a-technical-issue/ Thu, 21 Apr 2022 13:07:14 +0000 https://dopavision.com/?p=10175 REPORT A TECHNICAL ISSUE Technical Issue Form Return to Portal Home We encourage you to use this form to report technical issues you or participants may be experiencing. The information provided in this form goes directly to our Product team at Dopavision. One of our technical experts will review the report and get in touch […]

The post Report a Technical Issue appeared first on Dopavision.

]]>